

1 ***ELF5* is a respiratory epithelial cell-specific risk gene for severe COVID-19**

2 Maik Pietzner^{1,2,a}, Robert Lorenz Chua^{3,a}, Eleanor Wheeler², Katharina Jechow³, Helena Radbruch⁴,
3 Saskia Trump⁵, Bettina Heidecker⁶, Frank L. Heppner^{4,7,8}, Roland Eils^{3,9,10}, Marcus A. Mall^{10,11,12}, Leif-Erik
4 Sander¹³, Irina Lehmann^{5,10}, Sören Lukassen³, Nick Wareham², Christian Conrad^{3,b}, Claudia
5 Langenberg^{1,2,b*}

6 **Affiliations**

7 ¹Computational Medicine, Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin,
8 Germany

9 ²MRC Epidemiology Unit, University of Cambridge, Cambridge, UK

10 ³Center for Digital Health, Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin,
11 Germany

12 ⁴Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie
13 Universität Berlin und Humboldt-Universität zu Berlin, Berlin, Germany

14 ⁵Molecular Epidemiology Unit, Charité - Universitätsmedizin Berlin, corporate member of Freie
15 Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health (BIH), Berlin, Germany

16 ⁶Department of Cardiology, Charité – Universitätsmedizin Berlin, corporate member of Freie
17 Universität Berlin und Humboldt-Universität zu Berlin, Berlin, Germany

18 ⁷Cluster of Excellence, NeuroCure, Berlin, Germany

19 ⁸German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany

20 ⁹Health Data Science Unit, Heidelberg University Hospital and BioQuant, Heidelberg, Germany

21 ¹⁰German Center for Lung Research (DZL), associated partner site, Augustenburger Platz 1, 13353
22 Berlin, Germany

23 ¹¹Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-
24 Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu
25 Berlin, Berlin, Germany

26 ¹²Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany

27 ¹³Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin,
28 corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of
29 Health (BIH), Berlin, Germany

30 ^athese authors contributed equally to this work

31 ^bthese authors jointly supervised this work

32 **Correspondence**

33 Prof Claudia Langenberg (claudia.langenberg@bih-charite.de)

34 Prof Christian Conrad (christian.conrad@bih-charite.de)

35 Dr Maik Pietzner (maik.pietzner@bih-charite.de)

36

37

38

39

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

40

41 **ABSTRACT**

42 Despite two years of intense global research activity, host genetic factors that predispose to a poorer
43 prognosis and severe course of COVID-19 infection remain poorly understood. Here, we identified
44 eight candidate protein mediators of COVID-19 outcomes by establishing a shared genetic architecture
45 at protein-coding loci using large-scale human genetic studies. The transcription factor *ELF5* (*ELF5*)
46 showed robust and directionally consistent associations across different outcome definitions, including
47 a >4-fold higher risk (odds ratio: 4.85; 95%-CI: 2.65-8.89; p-value<3.1x10⁻⁷) for severe COVID-19 per 1
48 s.d. higher genetically predicted plasma *ELF5*. We show that *ELF5* is specifically expressed in epithelial
49 cells of the respiratory system, such as secretory and alveolar type 2 cells, using single-cell RNA
50 sequencing and immunohistochemistry. These cells are also likely targets of SARS-CoV-2 by
51 colocalisation with key host factors, including *ACE2* and *TMPRSS2*. We also observed a 25% reduced
52 risk of severe COVID-19 per 1 s.d. higher genetically predicted plasma G-CSF, a finding corroborated
53 by a clinical trial of recombinant human G-CSF in COVID-19 patients with lymphopenia reporting a
54 lower number of patients developing critical illness and death. In summary, large-scale human genetic
55 studies together with gene expression at single-cell resolution highlight *ELF5* as a novel risk gene for
56 COVID-19 prognosis, supporting a role of epithelial cells of the respiratory system in the adverse host
57 response to SARS-CoV-2.

58

59

60 INTRODUCTION


61 The COVID-19 pandemic, caused by the coronavirus SARS-CoV-2, has overwhelmed health care
62 systems all over the world and caused more than 5.1 million deaths. The unprecedented pace of
63 vaccine development, approval, and administration¹, has strongly reduced hospitalisations and
64 prevented hundreds of thousands of deaths², and only achieving population-wide immunity will end
65 the pandemic. However, it is unclear how long immunisation from vaccines or natural infection will
66 last³ and hospitalisation and death tolls remain high due to various factors, including the evolution of
67 novel SARS-CoV-2 variants⁴⁻⁶ and the missing availability of vaccines in low- and middle-income
68 countries⁷, requiring persistent efforts to identify host factors that predispose to poor outcomes.

69 So far, older age, male sex, smoking, obesity, social deprivation, ethnicity, and a high burden of pre-
70 existing conditions have been consistently identified as risk factors for a poor prognosis among COVID-
71 19 patients⁸⁻¹¹. However, a severe disease course, including hospitalisations and fatal outcomes also
72 occur in otherwise low-risk patients. Further, the biology underlying disease progression and fatal
73 outcomes remains largely unknown, with observational studies unable to dissect cause from
74 consequence. Common variation in the human genome has now been robustly linked to a higher
75 susceptibility to severe COVID-19 outcomes¹²⁻¹⁴, offering novel and orthogonal insights to deep
76 molecular profiling studies in patients employing single cell sequencing or immunoprofiling¹⁵⁻²⁰. For
77 example, common variants at 3p21.31 (possibly mapping to *LZTFL1* or *SLC6A20*) or 12q24.13 (likely
78 *OAS1*) confer 30%-110% higher risk for severe outcomes of COVID-19¹²⁻¹⁴, with suggested roles in
79 alveolar type 2 (AT2) cells^{16,21} or modulation of the host immune response^{22,23}. However, a major
80 obstacle to clinical translation of these findings is the identification of the causal genes through which
81 risk loci mediate their effect. Further, incorporating gene or protein expression quantitative trait loci
82 (QTLs) via statistical colocalisation or Mendelian randomization can highlight additional candidate
83 genes^{22,24-28}. Both techniques make use of a causal chain of events. Firstly, alleles are allocated at
84 random at conception providing the opportunity to use them as instruments for causal inference.
85 Secondly, genetic variants near protein-encoding loci (cis-pQTLs) that associate with protein levels in
86 healthy individuals before viral exposure can serve as instruments for lifelong exposure to higher or
87 lower protein levels. Therefore, establishing that the same genetic signal associates with protein levels
88 and a poor prognosis of COVID-19 provides strong evidence for a causal role of the protein in the
89 aetiology of the disease. This is particularly relevant for COVID-19, which is characterized by a
90 hyperimmune response and a profound impact on the plasma proteome²⁹ limiting insights from ad hoc
91 cross-sectional proteomic studies. Such genetically informed strategies have already identified
92 potential druggable targets, including *ACE2*²⁴, or modulators of the immune response such as *OAS1*²².

93 Here, we present a proteome-wide colocalisation screen, incorporating cis-pQTLs for more than 2,300
94 protein targets across two different platforms, to identify proteomic modulators of COVID-19
95 prognosis using genome-wide summary statistics for four different outcome definitions (ranging from
96 susceptibility to severity) as released by the COVID-19 Host Genetics Initiative³⁰
97 (<https://www.covid19hg.org/>, release 6) (**Fig. 1**). We demonstrate the ability of genetically informed
98 plasma proteomics to identify causal genes and proteins for severe COVID-19 and pinpoint the
99 responsible cell types through integration of orthogonal data.

100

101



102

103 **Figure 1. Flowchart of the study design.** We tested whether the same genetic signal that associated with
104 higher/lower protein abundances also associated with higher/lower risk for COVID-19 based on cis protein
105 quantitative trait loci (cis-pQTLs). We further investigated expression of targeted proteins/genes using single cell
106 and single nuclei RNA sequencing in samples of the respiratory system and confirmed expression of the most
107 robust candidate ELF5 using immunofluorescence staining.


108 RESULTS

109 *Putative protein mediators of disease risk*

110 We identified 6 previously unknown candidate causal proteins, in addition to replicating the
111 established candidates BGAT (encoded by *ABO*) and OAS1 (encoded by *OAS1*)^{22,24,25}, by systematically
112 testing for a shared genetic architecture at protein coding loci (± 500 kb) for 2375 protein targets (see
113 **Methods**) and COVID-19¹⁴ outcomes using statistical colocalisation (**Supplementary Table 1,**
114 **Methods**).

115 Of the 6 novel candidates, ELF5 showed significant and directionally consistent associations across all
116 four COVID-19 outcomes included as part of the COVID-19 Host Genetics Initiative
117 (<https://www.covid19hg.org/>)¹⁴, with strongest effects for more severe outcomes (**Fig. 2 and**
118 **Supplementary Table 2**) and strong evidence for a shared genetic signal for outcomes indicating a
119 poorer prognosis (hospitalisation and severe COVID-19; Posterior probability (PP)>80%). For example,
120 a 1 s.d. increase in genetically predicted ELF5 plasma abundances was associated with an almost 5-fold
121 higher risk for severe COVID-19 (odds ratio: 4.85; 95%-CI: 2.65-8.89; p-value<3.1x10⁻⁷) in a single-
122 instrument Mendelian randomization (MR) analysis using the lead cis protein quantitative trait locus
123 (cis-pQTL) as the genetic instrument (**Fig. 2, see Methods**).

124 The remaining candidate proteins showed robust evidence for selected COVID-19 outcomes in our
 125 initial analysis (Fig. 2), with G-CSF showing suggestive evidence (regional PP=64%) for a shared genetic
 126 signal with greater susceptibility to infection and more severe COVID-19 prognosis, using multi-trait
 127 colocalisation³¹ (Supplementary Fig. 1).




128
 129 **Figure 2. Proteins genetically linked to various COVID-19 outcomes.** Odds ratios and 95%-CIs for the genetically
 130 predicted effect of protein levels on four different outcome definitions and control populations for COVID-19
 131 (left), including protein targets with strong evidence for statistical colocalization for at least one definition (right).
 132 The column in the middle reports p-values. BGAT = Histo-blood group ABO system transferase; HSP 40 = DnaJ
 133 homolog subfamily B member 1; NUDT5 = ADP-sugar pyrophosphatase; RAB2A = Ras-related protein Rab-2A;
 134 ELF5 = ETS-related transcription factor Elf-5; OAS1 = 2'-5'-oligoadenylate synthase 1; SFTPD = Pulmonary
 135 surfactant-associated protein D; G-CSF = Granulocyte colony-stimulating factor

137 ***ELF5 is the candidate causal gene at 11p13 for severe COVID-19***

138 The lead cis-pQTL for ELF5, rs766826 (MAF=35.9%), is in strong linkage disequilibrium (LD;
139 $r^2=0.81$) with a recently identified variant rs61882275 associated with severe COVID-19 in an
140 independent study using whole genome sequencing³². The causal gene remained unidentified, but the
141 two closest candidate genes are *ELF5* and *CAT*, whose encoded protein products are both captured by
142 our proteomic data. We identify *ELF5* as the causal gene at this locus through a cluster of colocalising
143 phenotypes, including three different COVID-19 outcomes, *ELF5* expression in the lung, and ELF5
144 abundances in plasma (PP=93%), with rs766826 being the most likely (PP=99%) underlying causal
145 variant (**Fig. 3**). We further tested for colocalisation of the cis-pQTL for ELF5 and gene expression across
146 all GTEx tissues and identify colocalisation specific to expression in lung but not in other tissues,
147 including tissues with high ELF5 expression such as breast, prostate, or salivary glands (**Supplementary**
148 **Fig. 2**). This finding points towards a specific role of the major C-allele of rs766826 in increasing the
149 expression of *ELF5* in the lung (beta=0.24, p-value=5.3x10⁻¹⁵) with subsequent higher risk for severe
150 COVID-19 (odds ratio=1.11, p-value<5.0x10⁻⁶) and higher abundances of ELF5 in blood (beta=0.06, p-
151 value<5.4x10⁻⁶), the latter likely via cell turnover or injury of lung tissue since ELF5 is not predicted to
152 be actively secreted into blood³³.

153 While we identified strong evidence for a shared genetic signal (PP>80%) between the lead cis-pQTL
154 for the other candidate causal gene at this locus (*CAT*) and the corresponding cis-eQTL in 29 out of 49
155 tissues in GTEx v8, indicating convergence of gene and protein expression, plasma levels of catalase
156 (encoded by *CAT*) were unrelated to COVID-19 phenotypes. We further observed that *CAT* expression
157 in lung and whole blood formed a separate cluster (PP=56.6%) at the same genetic locus possibly
158 explained by rs35725681 (PP=36.8%, **Supplementary Fig. 3**).



159

160 **Figure 3. Stacked regional association plots at *ELF5*.** Each panel contains regional association statistics (p-values)
161 for the trait listed in the upper left corner along genomic coordinates. Each dots represents a single nucleotide
162 polymorphisms and colours indicate linkage disequilibrium (LD; r^2) with the most likely causal variant (rs766826)
163 at this locus (darker colours stronger LD). The position of rs766826 in the genome is highlighted by a red line the
164 lowest panel.

165

166

167 ***rs766826 resides in an open chromatin region in the lung and is associated with lung function***


168 While *ELF5* is known to be highly expressed in multiple tissues, we demonstrate that the
169 genetic signal shared between *ELF5*, severe COVID-19 prognosis, and gene expression was specific to
170 the lung. We observed that rs766826 mapped to an open chromatin region in AT2 cells from the lung
171 but not in other tissues with high expression of *ELF5*, such as mammary gland, prostate, or kidney
172 (**Supplementary Fig. 4**), providing a potential explanation for the tissue-specific effect.

173 To systematically test phenotypic consequences of rs766826 or proxies in strong LD ($r^2 > 0.8$), we
174 queried the OpenGWAS database³⁴ and performed colocalization for all suggestive associations
175 observed at $p < 10^{-4}$. The only association with evidence for a shared genetic signal with *ELF5* expression
176 and COVID-19 prognosis was seen for lung function (PP=99%) (**Supplementary Fig. 5**) with a somewhat
177 counterintuitive effect direction seen for the *ELF5*-increasing and COVID-19 risk C-allele being
178 associated with better lung function (beta=0.01, p-value $<1.6 \times 10^{-5}$) based on the quotient between
179 forced expired volume in 1 second (FEV₁) and forced vital capacity (FVC) from spirometry in population-
180 based, that is, COVID-19 free studies³⁵.

181 ***ELF5 is expressed in epithelial cells of the respiratory system***

182 We observed that *ELF5* was almost exclusively expressed by different epithelial cells of the
183 respiratory system (**Fig. 4**) using single cell and single nucleus RNA sequencing (scnRNAseq) across
184 different data sets of samples from healthy donors (**Fig. 4**, see **Methods**). Its expression pattern was
185 shared with the viral entry receptor *ACE2* and associated proteases, such as *TMPRSS2*. Specifically,
186 sustentacular and Bowman gland cells from the olfactory mucosa and secretory epithelial cells from
187 the pseudostratified epithelium of the nasopharynx and distal bronchioles of the lung showed high
188 expression levels of *ELF5* (**Fig. 4c**). They similarly expressed host proteins utilized by SARS-CoV-2,
189 including *ACE2* or *TMPRSS2*, suggesting that putative target cells of SARS-CoV-2 express high quantities
190 of *ELF5*.

191 Lungs from deceased COVID-19 patients consistently show signs of massive alveolar damage^{16,36}. While
192 *ELF5* expression was highest in secretory cells, AT2 but not AT1 cells showed consistent expression of
193 *ELF5* in our lung data set of COVID-19-free donors³⁷ (**Fig. 4**). This finding coincided with classical lineage
194 markers for AT2 cells such as *SFTPD*, which was also highly expressed in mitotic cells (**Fig. 4C**). We note
195 that our proteogenomic screen prioritised *SFTPD* as a candidate gene for severe COVID-19 in line with
196 other studies^{30,32}, leaving the possibility of potential interactions between candidate mediators.



197

198 **Figure 4. Expression of candidate genes in different single cell data sets covering the respiratory system.**
 199 UMAP representation of single cell/nuclei RNA sequencing data from three data sets (olfactory mucosa,
 200 nasopharynx, and lung) with annotations of cell types. **B** Expression levels of *ELF5* across all cells identified in all
 201 three data sets. **C** ACE2⁺ cells in all three data sets. **D** Dot plots showing the number of cells positive for candidate
 202 genes (size). The colour gradient indicates scaled average expression levels and red frames indicate significantly
 203 higher expression (adjusted p-value<0.05) of the target gene in one cell type compared to all others.


204 ***Immunofluorescence staining validates scnRNAseq results and shows high ELF5 expression in AT2***
205 ***cells of post-mortem COVID-19 samples***

206 We validated the expression of ELF5 at the protein level in the different epithelial cells of the olfactory
207 mucosa and lungs using immunofluorescence staining in non-COVID-19 samples (**Fig. 5** and
208 **Supplementary Figure 6 and 7**). Within the olfactory mucosa, sustentacular cells (KRT18⁺) and
209 horizontal basal cells (KRT18⁻) of the olfactory epithelium (above the dashed line, **Fig. 5A**) and the
210 Bowman gland cells (KRT18⁺) within the lamina propria (below the dashed line, **Fig. 5A**) were positively
211 stained for ELF5 (**Fig. 5A** and **Supplementary Figure 6A**). We further validated protein expression of
212 ELF5 in AT2 (SFTPC⁺) and epithelial cells (EPCAM⁺) of the airways in lung consistent with our scnRNAseq
213 experiments (**Fig. 5B-C** and **Supplementary Figure 6B-D**). We observed similar validation of scnRNAseq
214 experiments by immunofluorescence staining for ACE2 and TMPRSS2 (**Supplementary Figure 8**).

215 We next investigated ELF5 expression within the same tissues in samples from two patients who
216 rapidly died from severe COVID-19 within ≤ 14 days (**Fig. 5A-C**). We observed an injured olfactory
217 epithelium, including highly disrupted Bowman glands and very few cells showing ELF5 expression (**Fig.**
218 **5A**, left; **Supplementary Figure 6A**), and further loss of structural integrity of the alveolar region of the
219 lung with only very few AT2 cells within the damaged region. However, AT2 cells characterized by high
220 ELF5 expression also formed clusters, possibly reflective of their activated state to regenerate the
221 epithelia^{38,39} (**Fig. 5B** and **Supplementary Figure 6B**). Similarly, secretory cells (SCGB1A1⁺) along with
222 other epithelial cells of the airway mucosa (e.g., ciliated and basal cells) expressed ELF5 and were also
223 injured over the course of SARS-CoV-2 infection (**Fig. 5C**, **Supplementary Figure 6C-D**). These
224 observations suggest that *ELF5* expression might play a dynamic role during SARS-CoV-2 infection and
225 COVID-19.

226 We finally observed potential signs of remodeling and high ELF5 expression in post-mortem respiratory
227 tissue samples of two COVID-19 patients with a fatal but not rapid disease course due to intensive
228 treatment, including extracorporeal membrane oxygenation (≥ 14 days, termed as 'later death';
229 **Supplementary Figure 9A**). Mucosal structures were more similar to controls, although structural
230 integrity was not fully restored. We further observed potentially regenerative structures with either
231 AT2 cells or airway epithelial cells highly expressing ELF5 that may indicate an active wound healing
232 response³⁹⁻⁴¹ (**Supplementary Figure 9B-C**). Delorey *et al.* recently showed the induction of a
233 regenerative program in cells of the airway and alveolar epithelium after SARS-CoV-2 infection¹⁶.
234 However, AT2 cell renewal and AT1 cell differentiation were inhibited in COVID-19, leading to an
235 accumulation of cells in this regenerative transitional cell state and potentially lung failure¹⁶.

236



237

238 **Figure 5. ELF5 expression by epithelial cells of the olfactory mucosa and lung.** Immunofluorescent staining of
239 ELF5 in control and COVID-19 patients in the **A** olfactory mucosa, **B** lung alveoli, and **C** lung bronchiole. **A** Dashed
240 lines separate the olfactory epithelium and the lamina propria. **B** Arrowheads highlight AT2 cells expressing ELF5;
241 dashed outline highlights clusters of AT cells expressing ELF5. **C** left: epithelial cells expressing ELF5; right:
242 arrowheads highlight airway epithelial cells expressing ELF5. Marker genes for sustentacular and Bowman gland
243 cells (**A**, KRT18), alveoli type II cells (**B**, SFTPC), pan-epithelial cells (**C**, EPCAM), and secretory cells (**C**, SCGB1A1)
244 are shown in purple. Validation staining for each tissue: control (n=2); COVID-19 (n=2). Scale bar = 100 μ m

245

246 ***ELF5* and *TMPRSS2* are co-expressed**

247 To derive possible hypothesis of how *ELF5* expression might be linked to severe COVID-19, we
248 collated a list of candidate genes, that were either regulated or co-expressed with *ELF5* (see **Methods**
249 and **Supplementary Table 3**). Among the set of candidate genes were multiple members of the
250 transmembrane serine protease-family, including *TMPRSS2* and *TMPRSS4*, which have been shown to
251 be essential for viral entry by priming of the spike protein^{42,43}. We observed a positive correlation
252 between *ELF5* and *TMPRSS2* expression in sustentacular cells ($r=0.15$, $p<4.5\times 10^{-6}$, **Supplementary Fig.**
253 **10**), the cell type with highest *ELF5* expression in our data, but no correlation with *TMPRSS4* expression.
254 The correlation with *TMPRSS2* expression was also above the 95th percentile of correlation coefficients
255 across all genes. Further, genes highly correlated with *ELF5* expression were also significantly enriched


256 among collated target genes, minimizing the possibility of a measurement artefact. While such
257 correlation analysis using single-cell data must be treated with caution, overexpression of *Efl5* in a
258 mouse model showed a three-fold increase in *Ace2* and a two-fold higher expression of *Tmprss4* in AT2
259 cells⁴⁴, providing additional evidence that *ELF5* might be involved in the regulation of key host factors
260 for SARS-CoV-2.

261 To formally test for pathways associated with *ELF5* expression, we performed cell-type specific gene
262 set enrichment analysis using the collated set of putative ELF5 targets or co-expressed genes and
263 observed a consistent enrichment of biosynthetic pathways like mRNA and peptide processing and
264 possibly among genes involved in epithelial barrier formation (**Supplementary Fig. 11**). The latter aligns
265 with a substantial impact of *Elf5* overexpression on the differentiation of the lung epithelium in mouse
266 models of lung development, leading to dilation of the airways⁴⁴.

267

268 ***Drug target identification***

269 We queried all identified candidate genes in the Open Targets database⁴⁵ to identify repurposing
270 opportunities for COVID-19. While none of the genes had already approved drugs or drugs in clinical
271 trials, recombinant human G-CSF (rhG-CSF), such as filgrastim and lenograstim, is used to treat
272 neutropenia caused by chemotherapy to stimulate production of granulocytes from the bone
273 marrow⁴⁶. In line with this, phenotypic associations identified in a phenome-wide analysis of the lead
274 cis-pQTL for G-CSF showed that genetically higher plasma G-CSF was positively associated with
275 granulocyte and other white blood cell counts (**Fig. 6 and Supplementary Tab. 4**). This highlights the
276 ability of the cis-pQTL to instrument the function of the protein and allowed testing of the potential
277 effect of G-CSF supplementation for (severe) COVID-19 *in silico*. We observed a 25% (odds ratio: 0.75;
278 95%-CI: 0.65-0.87; p-value<1.5x10⁻⁴) reduction in the risk for severe COVID-19 per 1 s.d. higher
279 genetically predicted G-CSF (**Supplementary Tab. 2**). A previous smaller, independent study that used
280 a different proteomic technology observed directionally consistent results, but did not reach statistical
281 significance⁴⁷. Together, these results provide *in silico* evidence that people with genetically higher
282 plasma G-CSF abundances are less likely to develop severe COVID-19 and suggests that treatment with
283 rhG-CSF might decrease the risk for symptomatic or even severe COVID-19. A recent randomized
284 clinical trial⁴⁸ among 200 COVID-19 patients with pneumonia and severe lymphopenia observed a
285 significantly lower number of patients developing critical illness when treated within the first three
286 days of inclusion with 5µg/kg rhG-CSF. However, leucocytosis was common in the treatment arm,
287 including severe cases, which may limit the general application. For example, it might be conceivable
288 that rhG-CSF treatment in COVID-19 patients with a strong immune response stimulates an adverse
289 hyperinflammatory state and hence only a subgroup of COVID-19 patients might benefit.



290

291 **Figure 6. Convergence of genotype – phenotype variation at *GCSF3*.** Plot visualizing convergence of genetic
 292 variants at the *CSF3* locus in relation to the linkage disequilibrium (LD) with the candidate gene variant identified
 293 by multi-trait colocalisation (rs12600856). Z-scores from genome-wide association studies for each annotated
 294 trait have been scaled by the absolute maximum, and dot size is proportional to the LD (r^2). Colours indicate the
 295 direction of effect aligned to the risk-increasing allele (red – positive, blue - inverse). Effect estimates have been
 296 aligned to the protein increasing allele. Summary statistics for blood cell traits were obtained from Astle et al.⁴⁹,
 297 statistics for COVID-19 and protein abundances as described in the main text.

298

299 DISCUSSION

300 The identification of causal mechanisms that predispose infected individuals to a severe course
 301 of COVID-19, including hospitalisation and risk of death, can guide clinical management and the
 302 identification of novel drug targets or repurposing opportunities. We identified six not previously
 303 reported and replicated two known causal genes and their protein targets. We demonstrate that the
 304 strongest new and most robust candidate, *ELF5*, is specifically expressed in primary target cells of SARS-
 305 CoV-2 (for example, sustentacular⁵⁰, AT2⁵¹, and secretory or ciliated epithelial cells⁵²) with evidence of
 306 co-expression with genes encoding key host factors, such as *ACE2* and *TMPRSS2*, using scnRNAseq data
 307 across various sites of the respiratory system. We refine the association of genetic variation at *ELF5*
 308 with severe COVID-19 to a single causal variant (rs766826) with high confidence (PP=99%) and identify
 309 a tissue-specific effect of *ELF5* expression in lung that is associated with a more than 4-fold higher risk

310 to develop severe COVID-19. Our results highlight high *ELF5* expression in primary target cells of SARS-
311 CoV-2 as a possible mechanism for severe COVID-19 with a particular focus on epithelial cells.

312 We identify a total of eight candidate proteins with robust evidence for at least one outcome,
313 with Ets-related transcription factor Elf-5 (ELF5) being the most consistent not yet reported candidate
314 associated with a more than 4-fold higher genetically predicted risk for severe COVID-19. We show
315 that *ELF5* is specifically expressed in primary target cells of SARS-CoV-2 of the upper and lower
316 respiratory system, including sustentacular cells of the olfactory mucosa, secretory epithelial cells of
317 the nasopharynx, and AT2 cells in the lung using single cell/nuclei RNA sequencing and
318 immunohistochemistry. We further find genetically anchored evidence that aligns with a recent clinical
319 trial⁴⁸ suggesting human recombinant granulocyte colony-stimulating factor (G-CSF) as a potential
320 treatment option among patients with COVID-19 and severe lymphopenia to mitigate adverse
321 outcomes.

322 *ELF5* is a member of the Ets transcription factor family and is best known for its possible role in breast
323 or prostate cancer, tissues with high fractions of epithelial cells⁵³, and less for its possible role in lung
324 development^{44,54} and possibly cystic fibrosis⁵⁵. Experimental models to study the role of ELF5 are
325 difficult since *Elf5*^{-/-} mice are embryonic lethal. However, the recent development of transgenic mouse
326 models⁵⁶ and our scRNAseq data provide strong evidence that *ELF5* is expressed in epithelial cells of
327 the respiratory system of adult mice and humans. Early work in lung tissue cultures and mouse models
328 described a dynamic expression pattern of *Elf5* during embryogenesis and lung branching, including
329 almost complete downregulation in distal lung postnatally, while residual expression in proximal
330 airways persisted^{44,54}. Overexpression of *Elf5* during early but not late embryonal development (after
331 E16.5) caused a severe cystic lung phenotype characterised by disrupted branching and a dilated
332 airway epithelium⁴⁴, characteristics that are also seen in autopsies of COVID-19 patients³⁶. While such
333 a drastic intervention in mouse models is not comparable to the subtle effect of a common genetic
334 variant, the observation that key host factors for SARS-CoV-2 (*Ace2* and *Tmprss4*) are upregulated in
335 *Elf5*-overexpressing AT2 cells partly aligns with our observations using scRNAseq data.

336 The role of *ELF5* in secretory and AT2 cells of the airway and alveolar epithelium, respectively, may
337 have potential implications to the wound healing response. As cells with stem-like capacity, they are
338 involved in the maintenance and repair of their respective cellular niches^{38,57}. Thus, any surviving
339 secretory and AT2 cells that drive the repopulation of the epithelium could potentially have aberrant
340 repair programs mediated by *ELF5* and therefore possibly rs766826, if any, and an accumulation of AT2
341 cells in a regenerative transitional cell state has recently been suggested for COVID-19¹⁶.

342 Up to 60% of COVID-19 patients report transient anosmia⁵⁸, which is one of the few infectious
343 symptoms with high specificity⁵⁹. The underlying aetiology, however, remains largely elusive. Direct

344 infection and hence damage of olfactory sensory neurons by SARS-CoV-2 could be one obvious
345 explanation. Viral particles have been shown to be present in neuronal cells of the olfactory mucosa
346 possibly presenting a route for CNS infection⁶⁰, however, the generally undetectable expression levels
347 of *ACE2* in those cells makes them an unlikely primary target compared to, for example, epithelial
348 cells⁵⁰. Previous studies suggested that the loss of essential supporting cells, sustentacular cells, in the
349 olfactory mucosa causes anosmia^{50,61}. Sustentacular cells have been suggested as primary targets of
350 SARS-CoV-2 based on high *ACE2* expression^{50,51,62}, supported by *in vivo* models showing a high viral
351 load and rapid desquamation of the olfactory epithelium following infection^{63,64}. A finding in line with
352 our observations from samples of COVID-19 patients. Our observation that sustentacular cells, as well
353 as other secretory epithelial cells in the olfactory mucosa, express high levels of *ELF5* along with a
354 possible link to *ACE2* expression might indicate a possible modulating role of *ELF5* expression for this
355 common symptom. However, a recent GWAS for anosmia⁶⁵ among self-reported COVID-19 cases did
356 not yet identify rs766826 and hence *ELF5* expression. While this might be explained by limited
357 statistical power (the authors identified only one signal), it highlights that *ELF5* is likely only one out of
358 many host factors possibly contributing to the onset of anosmia during SARS-CoV-2 infection.

359 We provide genetically anchored evidence that people with higher plasma G-CSF abundances are less
360 likely to develop severe COVID-19, suggesting a possible protective effect possibly via early
361 recruitment of neutrophils to the entry sites of SARS-CoV-2⁶⁶. Colony-stimulating factors, such as G-
362 CSF, are haematopoietic growth factors and are actively investigated as treatment options for COVID-
363 19⁶⁷. A recent open-label, multicentre, randomized clinical trial⁴⁸ evaluated the efficacy of rhG-CSF to
364 improve symptoms among 200 COVID-19 patients with lymphopenia (lymphocyte cell count <800 per
365 μL) but without comorbidities. While no significant effect on the primary endpoint (time to
366 improvement) was detected, patients treated with rhG-CSF experienced significantly fewer severe
367 adverse effects, including respiratory failure, acute respiratory distress symptom, sepsis, or septic
368 shock⁴⁸. The treatment effect seemed further dependent on baseline lymphocyte counts, with
369 patients <400 per μL benefiting the most. However, leucocytosis was common in the treatment arm,
370 including severe cases. We note, that our results and the trial are in stark contrast to observational
371 studies associating higher G-CSF plasma levels^{68,69} and rhG-CSF treatment among cancer patients with
372 a poor prognosis^{70,71}, likely explained by the inability to distinguish cause and effect. We further
373 emphasize, that our genetically anchored drug prioritisation approach cannot make any
374 recommendations about the best timepoint and dose of intervention during the course of
375 infection/disease, which are crucial parameters for any drug application. Bespoke large randomized
376 clinical trials are warranted to evaluate optimal timing, dosage, and risk-benefit evaluation of rhG-CSF
377 treatment among COVID-19 patients.

378 Although the GWAS summary statistics from the COVID-19 Host Genetics Initiative represent multiple
379 ancestries and the signal at the *ELF5* locus has recently been replicated in a Brazilian cohort⁷², the pQTL
380 instruments are based on a single ancestry and genetic studies of plasma abundances of proteins in
381 other ancestries may reveal additional candidate proteins, that may help to explain the variable
382 prevalence of adverse COVID-19 outcomes across ethnicities⁸. We obtained some evidence that
383 rs766826 might act through a mechanism that is possibly unique to AT2 cells based on an open
384 chromatin region, the concrete underlying mechanism, however, remains elusive. Further studies are
385 needed to decipher the role of rs766826 in the cell-type specific expression of *ELF5*. The same holds
386 true for the suggested mechanisms of action for *ELF5*, for example co-expression with and possibly
387 regulation of *ACE2* or *TMPRSS2*, that need to be tested in appropriate cellular and animal models, also
388 to investigate the role of *ELF5* in tissues of the respiratory system more in general. Although our results
389 started with the investigation of proteins measured in plasma and might hence provide possible
390 biomarkers for severe COVID-19 in a clinical setting, we did not identify concordant associations based
391 on plasma proteomic profiling for most of the candidates in public data sets^{29,73}. This likely reflects a
392 general segregation of proteins that possibly cause a more severe outcome of COVID-19 from those
393 being a consequence of SARS-CoV-2 infection and COVID-19. We note that while MR can indicate
394 direction of effects, estimates should be interpreted with caution when plasma/blood is not the tissue
395 of action of the protein or if cis-pQTL(s) can be linked to protein altering variants or splicing event
396 QTLs⁷⁴, which likely explains the small effect sizes for BGAT (linked to a splicing QTL) or SFTPD (the cis-
397 pQTL, rs721917, being a missense variant, p.M31T).

398 Our results demonstrate potential modulators for a poor prognosis among COVID-19 patients with
399 potential therapeutic options. We identify *ELF5* as a potential regulator in cells that are the primary
400 targets of SARS-CoV-2 by combining population-level genetic evidence with gene expression at single-
401 cell resolution, providing tangible hypothesis for further functional follow-up studies to investigate the
402 role of *ELF5* for viral entry and wound healing of the epithelial layer of the respiratory system upon
403 severe COVID-19.

404

405 **METHODS and MATERIALS**

406 ***Summary statistics for proteins***

407 We obtained locus-specific, $\pm 500\text{kb}$ of the protein encoding gene, summary statistics from our
408 genome-wide association analysis for 4,775 plasma proteins targeted by the SomaScan v4 assay and
409 1,069 targeted by the Olink proximity extension assay^{28,75}. A detailed description can be found
410 elsewhere^{28,75}. Briefly, plasma abundances of 4,775 protein targets were tested for protein
411 quantitative trait loci using standard GWAS workflows based on 10.4 million single nucleotide
412 polymorphisms among 10,708 individuals of white British descent. We further obtained genome-wide
413 association statistics for 1,069 proteins measured using the complementary Olink technique available
414 among a subcohort of 485 participants. We tested all protein targets with at least suggestive evidence
415 ($p < 10^{-5}$) of a cis-pQTL or a COVID-19 signal close to the protein-encoding gene. We further treated
416 protein assays as separate instances even if those targeted the same protein between both techniques,
417 given the heterogeneity of genetic findings across both platforms⁷⁴. We tested a total of 2,375 protein
418 targets ($n=723$ common to both platforms) for colocalisation with any of the four COVID-19 outcome
419 definitions.

420 ***Summary statistics for COVID-19***

421 We used four meta-analysed COVID-19 data sets from the June 2021 release of the COVID-19 Host
422 Genetics Initiative (<https://www.covid19hg.org/results/r6/>), comprising A2 (very severe respiratory
423 confirmed COVID-19 vs. population), B1 (hospitalised COVID-19 vs. not hospitalised COVID-19), B2
424 (hospitalised COVID-19 vs. population), and C2 (COVID-19 vs. population). A summary of case
425 definitions can be found in Supplementary Table 1.

426 ***Statistical colocalisation***

427 To identify proteins that share a genetic architecture with any of the four different COVID-19 outcomes
428 we performed statistical colocalisation⁷⁶ in a 500kb window around the protein coding gene as
429 implemented in the R package *coloc*. Briefly, statistical colocalisation is a Bayesian approach that
430 provides posterior probabilities for each of five hypothesis: H0 – none of two traits has a genetic signal
431 in the region; H1 – only trait 1 has evidence for a genetic signal in the region; H2 – only trait 2 has
432 evidence for a genetic signal in the region; H3 – both traits have two distinct signals in the same
433 genomic region; and H4 – both traits share the same underlying genetic signal. We used default priors
434 and further restricted colocalisation analysis to regions with at least suggestive evidence for a cis-pQTL
435 ($p < 10^{-5}$). To accommodate the single variant assumption of *coloc*, we further required each protein-
436 outcome pair passing the PP threshold of 80% and that respective regional lead variants are in strong
437 LD ($r^2 > 0.8$). To further acknowledge the fact that some cis-pQTLs are likely driven by measurement

438 artefacts introduced by common but benign missense variation, we performed another round of
439 colocalisation conditioning on the lead cis-pQTL in the region, if we had such evidence.

440 ***Mendelian randomization***

441 To derive effect directions and estimate possible effects of life-long higher/lower protein abundances
442 on COVID-19 susceptibility and severeness, we performed single-instrument Mendelian randomization
443 (MR) analysis using cis protein quantitative trait loci (cis-pQTLs) as instruments. We computed the
444 Wald ratio⁷⁷ to derive an estimate for the causal effect of a 1 s.d. increase in plasma abundances of the
445 candidate protein on the risk for COVID-19.

446 ***Tissue gene expression***

447 We incorporated gene expression data by testing for a shared genetic signal between protein
448 abundance in plasma and expression of the protein encoding gene in one of at least 49 tissues of the
449 GTX v8 resource⁷⁸. We used the same colocalisation approach as described above.

450 ***Phenotypic follow-up of candidate cis-pQTLs***

451 We systematically tested for phenotypic associations for cis-pQTLs by querying the OpenGWAS³⁴
452 database, including proxies in high LD ($r^2 > 0.8$). To test for a shared genetic signal between the
453 FEV1/FCV ratio (a proxy for lung function) and plasma levels of ELF5, we downloaded genome-wide
454 summary statistics from Shrine et al.³⁵. We conditioned on two stronger independent lead signals in
455 the region (rs10836366 and rs1648123) to account for the single variant assumption in statistical
456 colocalisation.

457 ***Collation of target genes of ELF5***

458 We collated a list of genes with possible direction association with *ELF5* by querying the Molecular
459 Signatures Data Base⁷⁹, the Enricr tool⁸⁰, the Harmonizome⁸¹, including ChIP-Seq experiments⁸², and a
460 curated gene co-expression network⁸³ (**Supplementary Table 3**).

461 ***Single-cell/nucleus RNA sequencing***

462 Single-cell/nucleus RNA sequencing (sc/nRNA-seq) healthy control datasets of the olfactory mucosa
463 (GSE139522), nasopharynx (EGAS00001005461), and lungs (EGAS00001004689; EGAS00001004419:
464 SAMEA6848756, SAMEA6848761, SAMEA6848765, SAMEA6848766) were reanalyzed in this
465 study^{37,66,84,85}. Due to the increased noise of snRNA-seq data, we performed ambient RNA removal on
466 the lung dataset with SoupX v1.4.5⁸⁶. Analysis was performed with Seurat v3.1.4^{87,88}. For the olfactory
467 mucosa and lung datasets, individual samples were integrated and annotated from scratch. Individual
468 samples were subjected to a upper bound filter of <10% mitochondrial reads and >200 genes

469 expressed, and an upper bound filter of 3000-6000 genes depending on the sample. After log-
470 normalization and scaling, canonical correlation analysis was used for integration and batch-correction
471 of the individual samples. Principal component analysis and Uniform Manifold Approximation and
472 Projection for dimension reduction (UMAP) were calculated for each integrated dataset. Finally, after
473 unsupervised clustering, cell type assignment was performed as previously described^{15,37,50,66,84,85} and
474 marker genes are depicted in **Supplementary Figure 11**. Differentially expressed genes were identified
475 using a MAST-based differential expression test. The Pearson's correlation was calculated on log-
476 normalized expression values for all detected genes against *ELF5* in Sustentacular1 cells, which
477 expressed *ELF5* the highest. Gene set enrichment analysis⁷⁹ (GSEA; v4.1.0) was used to test for
478 enrichment of the collated *ELF5* target genes against all detected genes where the weights used were
479 the Pearson's correlation values. Utilizing the collated *ELF5* target genes, an *ELF5* target gene
480 expression score was calculated for all cells using the `AddModuleScore()` from Seurat.

481 ***Immunohistochemistry***

482 Postmortem olfactory mucosa and lung tissue were collected from control and COVID-19 donors. Non-
483 COVID-19 samples were obtained from the BrainBank/Biobank of the Department of Neuropathology
484 at the Charité – Universitätsmedizin Berlin (**Supplementary Tab. 5**). COVID-19 status from the
485 BrainBank/Biobank samples was assessed by Spindiang Rhonda PCR rapid COVID-19 test according to
486 the manufactures protocol. This study was approved by the local ethics committees (EA1/144/13,
487 EA2/066/20 and EA1/075/19) as well as by the Charité–BIH COVID-19 research board and was in
488 compliance with the Declaration of Helsinki; autopsies were performed on the legal basis of §1 of the
489 Autopsy Act of the state Berlin and §25(4) of the German Infection Protection Act. Control lung tissues
490 were purchased from OriGene (TissueFocus) and Tissue Solutions. Samples were embedded in paraffin
491 and sectioned at a 5µm thickness. Sections were deparaffinized in Roticlear (CarlRoth, A538.1) and
492 rehydrated with an ethanol series. Antigen retrieval was performed by submerging slides in 10mM
493 Sodium Citrate Buffer (Sigma-Aldrich, C999-1000ML) at 95°C for 10 minutes and left to cool for 30
494 minutes. Sections were permeabilized and blocked with 5% goat serum PBST (0.5% Triton X-100 in
495 PBS) for 1 hour. Primary antibodies (1% goat serum PBST) were then added onto the tissues and left
496 to incubate overnight. This was followed by secondary antibody (1% goat serum PBST) labelling for 1
497 hour at room temperature. Antibodies used in this study can be found in **Supplementary Table 6**.
498 TMPRSS2 with ACE2 staining was performed according to the instructions of VectaFluor™ Excel
499 Amplified Kit (Vector Laboratories; DK-2594). To remove autofluorescence, sections were sequentially
500 treated with Lipofuscin Autofluorescence Quencher (PromoCell, PK-CA707-23007) and Vector
501 TrueVIEW™ Kit (Vector Laboratories, SP-8400). Sections were then stained with 16µM Hoechst 33258

502 (ThermoFischer, H3569) for 5 minutes, washed with 1X PBS, and mounted with VECTASHIELD®
503 HardSet™ Antifade Mounting Medium (Vector Laboratories, H-1400-10). Stained slides were visualized
504 with a Leica SP8 confocal microscope. Images were processed and assembled with FIJI⁸⁹.

505 REFERENCES

- 506 1. Fauci, A. S. The story behind COVID-19 vaccines. *Science* **372**, 109 (2021).
507 2. Haas, E. J. *et al.* Infections, hospitalisations, and deaths averted via a nationwide vaccination
508 campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a
509 retrospective surveillance study. *Lancet. Infect. Dis.* **3099**, 1–10 (2021).
510 3. Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months after
511 infection. *Science* **371**, (2021).
512 4. Planas, D. *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
513 *Nature* **596**, 276–280 (2021).
514 5. Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in
515 England. *Science* **372**, (2021).
516 6. Lemey, P. *et al.* Untangling introductions and persistence in COVID-19 resurgence in Europe.
517 *Nature* **595**, 713–717 (2021).
518 7. Wagner, C. E. *et al.* Vaccine nationalism and the dynamics and control of SARS-CoV-2. *Science*
519 **373**, eabj7364 (2021).
520 8. Williamson, E. J. *et al.* Factors associated with COVID-19-related death using OpenSAFELY.
521 *Nature* **584**, 430–436 (2020).
522 9. Grasselli, G. *et al.* Risk Factors Associated with Mortality among Patients with COVID-19 in
523 Intensive Care Units in Lombardy, Italy. *JAMA Intern. Med.* **180**, 1345–1355 (2020).
524 10. Pijls, B. G. *et al.* Demographic risk factors for COVID-19 infection, severity, ICU admission and
525 death: a meta-analysis of 59 studies. *BMJ Open* **11**, e044640 (2021).
526 11. Gao, Y.-D. *et al.* Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy* **76**,
527 428–455 (2021).
528 12. Pairo-Castineira, E. *et al.* Genetic mechanisms of critical illness in COVID-19. *Nature* **591**, 92–
529 98 (2021).
530 13. Ellinghaus, D. *et al.* Genomewide Association Study of Severe Covid-19 with Respiratory
531 Failure. *N. Engl. J. Med.* (2020) doi:10.1056/NEJMoa2020283.
532 14. Initiative, C.-19 H. G. Mapping the human genetic architecture of COVID-19. *Nature* (2021)
533 doi:10.1038/s41586-021-03767-x.
534 15. Chua, R. L. *et al.* COVID-19 severity correlates with airway epithelium-immune cell
535 interactions identified by single-cell analysis. *Nat. Biotechnol.* **38**, 970–979 (2020).
536 16. Delorey, T. M. *et al.* COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets.
537 *Nature* **595**, 107–113 (2021).
538 17. Melms, J. C. *et al.* A molecular single-cell lung atlas of lethal COVID-19. *Nature* **595**, 114–119
539 (2021).
540 18. Karki, R. *et al.* Synergism of TNF- α and IFN- γ Triggers Inflammatory Cell Death, Tissue Damage,
541 and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. *Cell* **184**, 149-168.e17
542 (2021).
543 19. Lee, S. *et al.* Virus-induced senescence is driver and therapeutic target in COVID-19. *Nature*
544 (2021) doi:10.1038/s41586-021-03995-1.
545 20. Trump, S. *et al.* Hypertension delays viral clearance and exacerbates airway
546 hyperinflammation in patients with COVID-19. *Nat. Biotechnol.* **39**, 705–716 (2021).
547 21. Downes, D. J. *et al.* Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk
548 locus. *Nat. Genet.* (2021) doi:10.1038/s41588-021-00955-3.
549 22. Zhou, S. *et al.* A Neanderthal OAS1 isoform protects individuals of European ancestry against
550 COVID-19 susceptibility and severity. *Nat. Med.* **27**, 659–667 (2021).
551 23. Wickenhagen, A. *et al.* A prenylated dsRNA sensor protects against severe COVID-19. *Science*
552 **3**, eabj3624 (2021).
553 24. Gaziano, L. *et al.* Actionable druggable genome-wide Mendelian randomization identifies
554 repurposing opportunities for COVID-19. *Nat. Med.* **27**, 668–676 (2021).
555 25. Anisul, M. *et al.* A proteome-wide genetic investigation identifies several SARS-CoV-2-
556 exploited host targets of clinical relevance. *Elife* **10**, (2021).

- 557 26. Pathak, G. A. *et al.* Integrative genomic analyses identify susceptibility genes underlying
558 COVID-19 hospitalization. *Nat. Commun.* **12**, 4569 (2021).
- 559 27. Klaric, L. *et al.* Mendelian randomisation identifies alternative splicing of the FAS death
560 receptor as a mediator of severe COVID-19. *medRxiv Prepr. Serv. Heal. Sci.* 1–28 (2021)
561 doi:10.1101/2021.04.01.21254789.
- 562 28. Pietzner, M. *et al.* Mapping the proteo-genomic convergence of human diseases. *Science* **374**,
563 eabj1541 (2021).
- 564 29. Filbin, M. R. *et al.* Longitudinal proteomic analysis of severe COVID-19 reveals survival-
565 associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Reports Med.* **2**,
566 (2021).
- 567 30. Initiative, C.-19 H. G. & Ganna, A. Mapping the human genetic architecture of COVID-19: an
568 update. *medRxiv* 2021.11.08.21265944 (2021) doi:10.1101/2021.11.08.21265944.
- 569 31. Foley, C. N. *et al.* A fast and efficient colocalization algorithm for identifying shared genetic
570 risk factors across multiple traits. *Nat. Commun.* **12**, 764 (2021).
- 571 32. Kousathanas, A. *et al.* Whole genome sequencing identifies multiple loci for critical illness
572 caused by COVID-19. *medRxiv* 2021.09.02.21262965 (2021)
573 doi:10.1101/2021.09.02.21262965.
- 574 33. Uhlén, M. *et al.* The human secretome. **0274**, 1–9 (2019).
- 575 34. Elsworth, B. *et al.* The MRC IEU OpenGWAS data infrastructure. *bioRxiv* 2020.08.10.244293
576 (2020) doi:10.1101/2020.08.10.244293.
- 577 35. Shrine, N. *et al.* New genetic signals for lung function highlight pathways and chronic
578 obstructive pulmonary disease associations across multiple ancestries. *Nat. Genet.* **51**, 481–
579 493 (2019).
- 580 36. Carsana, L. *et al.* Pulmonary post-mortem findings in a series of COVID-19 cases from northern
581 Italy: a two-centre descriptive study. *Lancet Infect. Dis.* **20**, 1135–1140 (2020).
- 582 37. Lukassen, S. *et al.* SARS-CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in
583 bronchial transient secretory cells. *EMBO J.* **39**, 1–15 (2020).
- 584 38. Barkauskas, C. E. *et al.* Type 2 alveolar cells are stem cells in adult lung. *J. Clin. Invest.* **123**,
585 3025–36 (2013).
- 586 39. Desai, T. J., Brownfield, D. G. & Krasnow, M. A. Alveolar progenitor and stem cells in lung
587 development, renewal and cancer. *Nature* **507**, 190–4 (2014).
- 588 40. Tata, P. R. *et al.* Dedifferentiation of committed epithelial cells into stem cells in vivo. *Nature*
589 **503**, 218–23 (2013).
- 590 41. Rock, J. R. *et al.* Multiple stromal populations contribute to pulmonary fibrosis without
591 evidence for epithelial to mesenchymal transition. *Proc. Natl. Acad. Sci. U. S. A.* **108**, E1475–83
592 (2011).
- 593 42. Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a
594 Clinically Proven Protease Inhibitor. *Cell* **181**, 271–280.e8 (2020).
- 595 43. Zang, R. *et al.* *TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal*
596 *enterocytes. Sci. Immunol* vol. 5 <https://www.science.org> (2020).
- 597 44. Metzger, D. E., Stahlman, M. T. & Shannon, J. M. Misexpression of ELF5 disrupts lung
598 branching and inhibits epithelial differentiation. *Dev. Biol.* **320**, 149–160 (2008).
- 599 45. Ochoa, D. *et al.* Open Targets Platform: supporting systematic drug-target identification and
600 prioritisation. *Nucleic Acids Res.* **49**, D1302–D1310 (2021).
- 601 46. Gunzer, K. *et al.* Contribution of glycosylated recombinant human granulocyte colony-
602 stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.
603 *Expert Opin. Biol. Ther.* **10**, 615–630 (2010).
- 604 47. Li, M., Ho, C., Yeung, C. H. C. & Schooling, C. M. Circulating Cytokines and Coronavirus Disease:
605 A Bi-Directional Mendelian Randomization Study. *Front. Genet.* **12**, 680646 (2021).
- 606 48. Cheng, L.-L. *et al.* Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for
607 Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical
608 Trial. *JAMA Intern. Med.* **181**, 71–78 (2021).
- 609 49. Astle, W. J. *et al.* The Allelic Landscape of Human Blood Cell Trait Variation and Links to

- 610 Common Complex Disease. *Cell* **167**, 1415-1429.e19 (2016).
- 611 50. Brann, D. H. *et al.* Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system
612 suggests mechanisms underlying COVID-19-associated anosmia. *Sci. Adv.* **6**, 5801–5832
613 (2020).
- 614 51. Muus, C. *et al.* Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and
615 demographics. *Nat. Med.* **27**, 546–559 (2021).
- 616 52. Hou, Y. J. *et al.* SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the
617 Respiratory Tract. *Cell* **182**, 429-446.e14 (2020).
- 618 53. Piggitt, C. L. *et al.* ELF5 isoform expression is tissue-specific and significantly altered in cancer.
619 *Breast Cancer Res.* **18**, 1–18 (2016).
- 620 54. Metzger, D. E., Xu, Y. & Shannon, J. M. Elf5 Is an Epithelium-Specific, Fibroblast Growth
621 Factor-Sensitive Transcription Factor in the Embryonic Lung. *Dev. Dyn.* **236**, 1175–1192
622 (2007).
- 623 55. Swahn, H. *et al.* Coordinate regulation of ELF5 and EHF at the chr11p13 CF modifier region. *J.*
624 *Cell. Mol. Med.* **23**, 7726–7740 (2019).
- 625 56. Singh, S. *et al.* A new Elf5CreERT2-GFP BAC transgenic mouse model for tracing Elf5 cell
626 lineages in adult tissues. *FEBS Lett.* **593**, 1030–1039 (2019).
- 627 57. Rawlins, E. L. *et al.* The role of Scgb1a1+ Clara cells in the long-term maintenance and repair
628 of lung airway, but not alveolar, epithelium. *Cell Stem Cell* **4**, 525–34 (2009).
- 629 58. Menni, C. *et al.* Real-time tracking of self-reported symptoms to predict potential COVID-19.
630 *Nat. Med.* **26**, 1037–1040 (2020).
- 631 59. Struyf, T. *et al.* Signs and symptoms to determine if a patient presenting in primary care or
632 hospital outpatient settings has COVID-19. *Cochrane database Syst. Rev.* **2**, CD013665 (2021).
- 633 60. Meinhardt, J. *et al.* Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous
634 system entry in individuals with COVID-19. *Nat. Neurosci.* **24**, 168–175 (2021).
- 635 61. Khan, M. *et al.* Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the
636 respiratory and olfactory mucosae but spares the olfactory bulb. *Cell* 100264 (2021)
637 doi:10.1016/j.cell.2021.10.027.
- 638 62. Fodoulian, L. *et al.* SARS-CoV-2 Receptors and Entry Genes Are Expressed in the Human
639 Olfactory Neuroepithelium and Brain. *iScience* **23**, 101839 (2020).
- 640 63. Bryche, B. *et al.* Massive transient damage of the olfactory epithelium associated with
641 infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. *Brain. Behav.*
642 *Immun.* **89**, 579–586 (2020).
- 643 64. Ye, Q. *et al.* SARS-CoV-2 infection in the mouse olfactory system. *Cell Discov.* **7**, 49 (2021).
- 644 65. Shelton, A. J. F., Shastri, A. J., Team, T. C.- & Aslibekyan, S. The UGT2A1 / UGT2A2 locus is
645 associated with COVID-19-related anosmia. (2021).
- 646 66. Loske, J. *et al.* Pre-activated antiviral innate immunity in the upper airways controls early
647 SARS-CoV-2 infection in children. *Nat. Biotechnol.* (2021) doi:10.1038/s41587-021-01037-9.
- 648 67. Lang, F. M., Lee, K. M. C., Teijaro, J. R., Becher, B. & Hamilton, J. A. GM-CSF-based treatments
649 in COVID-19: reconciling opposing therapeutic approaches. *Nat. Rev. Immunol.* **20**, 507–514
650 (2020).
- 651 68. Mudd, P. A. *et al.* Distinct inflammatory profiles distinguish COVID-19 from influenza with
652 limited contributions from cytokine storm. *Sci. Adv.* **6**, 16–18 (2020).
- 653 69. Meizlish, M. L. *et al.* A neutrophil activation signature predicts critical illness and mortality in
654 COVID-19. *Blood Adv.* **5**, 1164–1177 (2021).
- 655 70. Zhang, A. W. *et al.* The Effect of Neutropenia and Filgrastim (G-CSF) on Cancer Patients With
656 Coronavirus Disease 2019 (COVID-19) Infection. *Clin. Infect. Dis.* **2019**, 1–8 (2021).
- 657 71. Sereno, M. *et al.* A Multicenter Analysis of the Outcome of Cancer Patients with Neutropenia
658 and COVID-19 Optionally Treated with Granulocyte-Colony Stimulating Factor (G-CSF): A
659 Comparative Analysis. *Cancers (Basel)*. **13**, (2021).
- 660 72. Pereira, A. C. *et al.* Genetic risk factors and Covid-19 severity in Brazil: results from BRACOV
661 Study. *medRxiv* 2021.10.06.21264631 (2021) doi:10.1101/2021.10.06.21264631.
- 662 73. Overmyer, K. A. *et al.* Large-Scale Multi-omic Analysis of COVID-19 Severity. *Cell Syst.* 1–18

- 663 (2020) doi:10.1016/j.cels.2020.10.003.
- 664 74. Pietzner, M. *et al.* Cross-platform proteomics to advance genetic prioritisation strategies.
665 *bioRxiv* 2021.03.18.435919 (2021) doi:10.1101/2021.03.18.435919.
- 666 75. Pietzner, M. *et al.* Synergistic insights into human health from aptamer- and antibody-based
667 proteomic profiling. *Nat. Commun.* **12**, 6822 (2021).
- 668 76. Giambartolomei, C. *et al.* Bayesian test for colocalisation between pairs of genetic association
669 studies using summary statistics. *PLoS Genet.* **10**, e1004383 (2014).
- 670 77. Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N. & Davey Smith, G. Mendelian
671 randomization: using genes as instruments for making causal inferences in epidemiology. *Stat.*
672 *Med.* **27**, 1133–63 (2008).
- 673 78. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human
674 tissues. *Science* **369**, 1318–1330 (2020).
- 675 79. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for
676 interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–50
677 (2005).
- 678 80. Kuleshov, M. V. *et al.* Enrichr: a comprehensive gene set enrichment analysis web server 2016
679 update. *Nucleic Acids Res.* **44**, W90-7 (2016).
- 680 81. Rouillard, A. D. *et al.* The harmonizome: a collection of processed datasets gathered to serve
681 and mine knowledge about genes and proteins. *Database (Oxford)*. **2016**, 1–16 (2016).
- 682 82. Kalyuga, M. *et al.* ELF5 suppresses estrogen sensitivity and underpins the acquisition of
683 antiestrogen resistance in luminal breast cancer. *PLoS Biol.* **10**, e1001461 (2012).
- 684 83. Deelen, P. *et al.* Improving the diagnostic yield of exome- sequencing by predicting gene-
685 phenotype associations using large-scale gene expression analysis. *Nat. Commun.* **10**, 2837
686 (2019).
- 687 84. Gassen, N. C. *et al.* SARS-CoV-2-mediated dysregulation of metabolism and autophagy
688 uncovers host-targeting antivirals. *Nat. Commun.* **12**, 3818 (2021).
- 689 85. Durante, M. A. *et al.* Single-cell analysis of olfactory neurogenesis and differentiation in adult
690 humans. *Nat. Neurosci.* **23**, 323–326 (2020).
- 691 86. Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based
692 single-cell RNA sequencing data. *Gigascience* **9**, 1–10 (2020).
- 693 87. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
694 transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.*
695 **36**, 411–420 (2018).
- 696 88. Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-1902.e21 (2019).
- 697 89. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**,
698 676–82 (2012).
- 699
- 700

701 **ACKNOWLEDGEMENTS**

702 We are grateful to all Fenland volunteers and to the General Practitioners and practice staff for
703 assistance with recruitment. We thank the Fenland Study Investigators, Fenland Study Co-ordination
704 team and the Epidemiology Field, Data and Laboratory teams. Proteomic measurements were
705 supported and governed by a collaboration agreement between the University of Cambridge and
706 SomaLogic.

707 **FUNDING**

708 The Fenland Study (10.22025/2017.10.101.00001) is funded by the Medical Research Council
709 (MC_UU_12015/1). We further acknowledge support for genomics from the Medical Research Council
710 (MC_PC_13046). CL, EW, MP, and NJW are funded by the Medical Research Council (MC_UU_00006/1
711 - Aetiology and Mechanisms). Non-COVID-19 autopsy samples were provided by the
712 BrainBank/BioBank of the Department of Neuropathology at the Charité – Universitätsmedizin Berlin,
713 funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under
714 Germany’s Excellence Strategy – EXC-2049 – 390688087. COVID-19 autopsies were supported by the
715 the German Network University Medicine NUM FKZ 01KX2021 Organostrat and Defeat Pandemics
716 (H.R. and F.L.H.).

717 **AUTHOR CONTRIBUTIONS**

718 Conceptualization: CL, MP, CC
719 Data curation/Software: MP, RLC, SL, EW
720 Formal Analysis: MP, RLC, SL, EW
721 Methodology: SL, ST
722 Visualization: MP, RLC, SL, KJ
723 Experiments: RLC, KJ, HR
724 Funding acquisition: CL, NJW, CC, IL, RE
725 Project administration: CL, NJW, CC, RE, IL
726 Supervision: CL, CC
727 Writing – original draft: MP, RCL, SL, CC, CL
728 Writing – review & editing: EW, HR, ST, BH, RE, MM, LS, IL, NJW

729 **COMPETING INTERESTS**

730 All other authors declare that they have no competing interests.

731 **DATA and MATERIALS AVAILABILITY**

732 Summary statistics for protein levels are available from www.omicscience.org. Summary statistics for
733 COVID-19 are available from <https://www.covid19hg.org/results/r6/>. scRNAseq data sets are available
734 under the accession IDs: olfactory mucosa (GSE139522), nasopharynx (EGAS00001005461), and lungs
735 (EGAS00001004689, EGAS00001004419, SAMEA6848756, SAMEA6848761, SAMEA6848765,
736 SAMEA6848766). Associated code and scripts for the analysis will be made available on GitHub upon
737 publication (https://github.com/pietznerm/elf5_covid19).

738

739